Carbidopa and levodopa recalls
The FDA has published 3 recalls involving Carbidopa and levodopa since 2014. The latest was reported on 8 Mar 2023. Most were for packaging defects. Teva Pharmaceuticals U has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls3since 2014
Last 12 months0reported
Class I00% of total
Ongoing0latest 8 Mar 2023
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 3 100%Class III 0 0%
Why carbidopa and levodopa is recalled
Companies
By year
All carbidopa and levodopa recalls, newest first
3 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Carbidopa and Levodopa Tablets, USP 25 mg/100 mg, Unit Dose recalled | The Harvard Drug Group | Packaging Defects | Nationwide |
| Drug | CLASS II | Carbidopa and Levodopa Tablets, USP 25 mg/250mg recalled by Mayne Pharma | Mayne Pharma | Packaging Defects | Nationwide |
| Drug | CLASS II | Carbidopa and Levodopa Tablets USP, 25mg/100mg recalled | Teva Pharmaceuticals U | Potency & Assay | Nationwide |
Should you stop taking Carbidopa and levodopa?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.